Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Pain, Postoperative 3Head and Neck Neoplasms 2Trigger Finger Disorder 1Stomatitis 1Skin Neoplasms 1Rectal Neoplasms 1Pain 1Multiple Myeloma 1Mucositis 1Median Neuropathy 1Lymphoma 1Ileus 1Ganglion Cysts 1Diverticulosis, Colonic 1Diverticulitis, Colonic 1De Quervain Disease 1Constipation 1Colonic Neoplasms 1Breast Neoplasms 1Agnosia 1Abnormalities, Radiation-Induced 1

Interventions

pembrolizumab 23Nivolumab 22aldesleukin 21Cyclophosphamide 20Ipilimumab 17Interleukin-2 17fludarabine 15fludarabine phosphate 14cemiplimab 12Radiotherapy 7Fluorouracil 7Dacarbazine 6binimetinib 5Vemurafenib 5Temozolomide 5Surgical Procedures, Operative 5Sirolimus 5Radiation 5Biopsy 5Aminolevulinic Acid 5encorafenib 4dabrafenib 4Photochemotherapy 4Educational Status 4trametinib 3sonidegib 3montanide ISA 51 3avelumab 3Tacrolimus 3Sodium Chloride 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Skin Neoplasms × oxycodone-acetaminophen × Clear all
NCT07575230 2026-05-11

Suzetrigine vs Norco-postoperative Mohs Pain

Baylor Research Institute

Phase 4 Enrolling by invitation
75 enrolled
Dermatologic

Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡